tiprankstipranks
Trending News
More News >

Clover Biopharmaceuticals Disputes Gavi’s Termination and Repayment Claim

Story Highlights
Clover Biopharmaceuticals Disputes Gavi’s Termination and Repayment Claim

Don’t Miss TipRanks’ Half-Year Sale

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) just unveiled an announcement.

Clover Biopharmaceuticals Ltd. has announced that its subsidiary, Clover HK, received a notice from Gavi Alliance regarding the unilateral termination of their Advance Purchase Agreement and a claim for repayment of $224 million. Clover Biopharmaceuticals disputes the claim, asserting it is without merit and plans to defend itself vigorously. The company continues to focus on advancing its RSV vaccine candidate, SCB-1019, in a re-vaccination setting and as part of a respiratory combination vaccine.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. is a company in the biopharmaceutical industry, focusing on the development of vaccines, including COVID-19 and RSV vaccine candidates. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.

YTD Price Performance: 34.85%

Average Trading Volume: 1,618,911

Technical Sentiment Signal: Hold

Current Market Cap: HK$421.5M

Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1